On Thursday, Shares of Tesla Motors Inc (NASDAQ:TSLA), lost -8.88% to $246.13.
Tesla Motors released its financial results for the second quarter ended June 30, 2015, by posting the current Shareholder Letter on its website.
As formerly declared, Tesla administration will host a live question & answer (Q&A) webcast at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time) to talk about the results and outlook.
Tesla Motors, Inc. designs, develops, manufactures, and sells electric vehicles, electric vehicle powertrain components, and stationary energy storage systems in the United States, China, Norway, and internationally. It also provides development services to develop electric vehicle powertrain components and systems for other automotive manufacturers.
Shares of CF Industries Holdings, Inc. (NYSE:CF), inclined 2.24% to $63.00, during its last trading session.
CF Industries Holdings, and OCI N.V., declared that they have reached a definitive agreement under which CF will combine with OCI’s European, North American and Global Distribution businesses in a transaction valued at about $8 billion, based on CF’s current share price, counting the assumption of about $2 billion in net debt.
The transaction, which has been unanimously approved by the boards of directors of both companies, will create the world’s largest publicly traded nitrogen company. The transaction comprises OCI’s nitrogen production facilities in Geleen, Netherlands, and Wever, Iowa, and the company’s interest in an ammonia and methanol complex in Beaumont, Texas, together with its global distribution business based in Dubai, United Arab Emirates. The combined entity will also purchase a 45 percent interest plus an option to acquire the remaining interest in OCI’s Natgasoline project in Texas, which upon completion in 2017 will be one of the world’s largest methanol facilities. On a combined basis the company will have production capacity of about 12 million nitrogen-equivalent nutrient tons by mid-year 20161.
CF Industries Holdings, Inc. manufactures and distributes nitrogen fertilizers and other nitrogen products worldwide. The company’s principal nitrogen fertilizer products comprise ammonia, granular urea, and urea ammonium nitrate solution. Its other nitrogen products comprise ammonium nitrate, diesel exhaust fluid, urea liquor, and aqua ammonia.
Finally, Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), ended its last trade with -4.47% loss, and closed at $18.39.
Aegerion Pharmaceuticals, declared its financial results and business highlights for the second quarter of 2015.
Highlights
- Aegerion recorded $57.1 million in net product sales of JUXTAPID(R) (lomitapide) capsules in the second quarter of 2015, representing growth of about 59% over the second quarter of 2014. 96% of JUXTAPID net product sales in the second quarter of 2015 were from prescriptions written in the United States.
- Aegerion recorded $7.1 million in net product sales of MYALEPT(R) (metreleptin for injection) in the second quarter of 2015, all of which were from prescriptions written in the United States. As of July 31, 2015, 68 generalized lipodystrophy (GL) patients were active on commercial therapy.
- Aegerion’s cash raised by $15.2 million in the second quarter of 2015.
- The Company is on track with its plan to file a Japanese NDA for lomitapide in adult HoFH patients late 2015 or early 2016. The Company anticipates a nine month review period as a result of lomitapide’s orphan drug status.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies for patients with debilitating rare diseases in the United States. The company’s products comprise JUXTAPID (lomitapide) capsules, an adjunct to a low-fat diet and other lipid-lowering treatments, counting low-density lipoprotein, low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein cholesterol in adult patients with homozygous familial hypercholesterolemia (HoFH); and LOJUXTA (lomitapide) hard capsule used as a treatment for HoFH in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
